Baxter International's BioPharma Solutions business is expanding its facility in Halle, Germany with an additional 1,750 square meters at its cytotoxic fill/finish contract manufacturing facility. The expansion allows the company to support early phase drug formulation through commercial scale-up , product launch and lifecycle management. 
 
The expansion includes the installation of a new commercial filling line with two freeze dryers, as well as a clinical filling line with an additional freeze dryer. Both will be equipped with an automated loading/unloading, capping and inspection infrastructure. The expansion is scheduled for completion in 2015.
 
"Cancer incidence is on the rise and cytotoxic therapies continue to be at the center of oncology treatment programs," said Dr. Burkhard Wichert, vice president of manufacturing for Baxter's BioPharma Solutions business. "Through this expansion in Halle, Baxter will continue to support pharmaceutical companies' efforts to address patient needs worldwide."
 
"We believe in our customers and the patients they serve, which is why we continue to invest in the Halle, Germany facility," said Dr. Wichert. "This expansion and our advanced technologies allow Baxter to stay at the forefront of parenteral cytotoxic manufacturing while increasing the current Halle workforce by approximately 10%."